Daniel P. Fitzgerald
Research Subjects
Daniel P. Fitzgerald has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Ana Paucarmayta
NextCure Inc., Beltsville, MD 20705, USA
1 shared publication- Chuan Yan
Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore
1 shared publication - Dallas B. Flies
NextCure Inc , Beltsville, MD
1 shared publication David M. Langenau
Molecular Pathology and Cancer Center, Massachusetts General Hospital Research Institute, Charlestown, MA 02129, USA
1 shared publication- Dorothy M. Johnson
NextCure Inc., Beltsville, MD 20705, USA
1 shared publication Jahangheer Shaik
NextCure Inc., Beltsville, MD 20705, USA
1 shared publication
Latest Publications
- Open Access
- 1 March 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (9) , eadj4698
The FLRT3-UNC5B checkpoint pathway inhibits T cell–based cancer immunotherapies
Cancers exploit coinhibitory receptors on T cells to escape tumor immunity, and targeting such mechanisms has shown remarkable clinical benefit, but in a limited subset of patients. We hypothesized that cancer cells mimic noncanonical mechanisms of early development such as axon guidance pathways to evade T cell immunity. Using gain-of-function genetic screens, we profiled axon guidance proteins on human T cells and their cognate ligands and identified fibronectin leucine-rich transmembrane protein 3 (FLRT3) as a ligand that inhibits T cell activity. We demonstrated that FLRT3 inhibits T cells through UNC5B, an axon guidance receptor that is up-regulated on activated human T cells. FLRT3 expressed in human cancers favored tumor growth and inhibited CAR-T and BiTE + T cell killing and infiltration in humanized cancer models. An FLRT3 monoclonal antibody that blocked FLRT3-UNC5B interactions reversed these effects in an immune-dependent manner. This study supports the concept that axon guidance proteins mimic T cell checkpoints and can be targeted for cancer immunotherapy.
- 1 March 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (9) , eadj4698
Open AccessThe FLRT3-UNC5B checkpoint pathway inhibits T cell–based cancer immunotherapies
Cancers exploit coinhibitory receptors on T cells to escape tumor immunity, and targeting such mechanisms has shown remarkable clinical benefit, but in a limited subset of patients. We hypothesized that cancer cells mimic noncanonical mechanisms of early development such as axon guidance pathways to evade T cell immunity. Using gain-of-function genetic screens, we profiled axon guidance proteins on human T cells and their cognate ligands and identified fibronectin leucine-rich transmembrane protein 3 (FLRT3) as a ligand that inhibits T cell activity. We demonstrated that FLRT3 inhibits T cells through UNC5B, an axon guidance receptor that is up-regulated on activated human T cells. FLRT3 expressed in human cancers favored tumor growth and inhibited CAR-T and BiTE + T cell killing and infiltration in humanized cancer models. An FLRT3 monoclonal antibody that blocked FLRT3-UNC5B interactions reversed these effects in an immune-dependent manner. This study supports the concept that axon guidance proteins mimic T cell checkpoints and can be targeted for cancer immunotherapy.